Journal Menu► ▼ Journal Menu
Journal Browser► ▼ Journal Browser
Special Issue "Prion Disease Biomarkers: Recent Advances"
Deadline for manuscript submissions: 15 February 2020.
Interests: prion diseases; rapidly progressive dementias and neurodegeneratve diseases; development and implemention of new biomarker platforms for disease diagnosis; prognosis and disease monitoring; molecular neuropathology of human neurodegenarative diseases
Prion diseases or transmissible spongiform encephalopathies (TSEs) are a family of rare and fatal progressive neurodegenerative disorders caused by prions, which are the abnormal and pathogenic forms of the cellular prion protein (PrP), affecting humans and animals.
In humans, prion diseases are classified according to their etiology in sporadic (sporadic Creutzfeldt–Jakob disease—the most prevalent form accounting for approximately 85% of all prion disease cases), genetic (genetic Creutzfeld–Jakob disease, fatal familial insomnia, and Gerstmann–Sträussler–Scheinker syndrome), and acquired (iatrogenic Creutzfeldt–Jakob disease, variant Creutzfeldt–Jakob disease, and kuru) forms.
Prion disease can exhibit a variety of clinical manifestations that make their differential diagnosis challenging. Indeed, definite diagnosis is only possible through neuropathological examination of the pathological isoform of the prion protein (PrPSc) in the central nervous system through a biopsy or autopsy. However, implementation in clinical settings over the last few decades of fluid and neuroimaging biomarkers has generated a set of assays displaying high accuracies in the discrimination of prion diseases. Some of these assays are already included in the diagnostic criteria for these conditions.
Despite great advances in the diagnosis of prion disease-symptomatic individuals, early diagnosis is still challenging due to the absence of a long pre-symptomatic phase, in contrast to what occurs in other neurodegenerative diseases, such as Alzheimer’s disease. Less is known about the role of current biomarkers in disease prognosis in terms of predicting the severity and rapidity of the disease. Similarly, the use of prion biomarkers as potential tools for the evaluation of the efficacy of disease-modifying therapies in therapeutic trials is still in its infancy.
In this Special Issue of Biomolecules called “Prion Disease Biomarkers: Recent Advances”, we would like to explore recent aspects in the field of prion biomarker research, especially in new aspects related to disease diagnosis and prognosis, as well as the potential contribution of prion biomarkers in the design and interpretation of eventual clinical trials.
Dr. Franc Llorens
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- prion diseases
- cerebrospinal fluid
- disease monitoring